Formulary Apportionment in Corporate Taxation

Instead of trying to price internal transfers between subsidiaries—a process called arm’s-length pricing—some countries and tax authorities use formulary apportionment: a mechanical formula that splits a multinational’s total profit according to the share of its sales, payroll, assets, or a weighted average in each jurisdiction. Formulary apportionment corporate tax allocation is simpler and cheaper to enforce, but it redistributes tax revenue and invites political conflict over the formula weights.

The Transfer Pricing Problem

A multinational corporation operates in many countries. It manufactures in Mexico, does R&D in the U.S., sells in Japan. Internally, it transfers goods and intellectual property between subsidiaries. These internal transfers have a price—a “transfer price”—that determines how much profit is taxed in each country.

The OECD and most tax authorities use the “arm’s-length principle”: the internal price should match what unrelated firms would charge. An independent company would not sell at a loss. So the transfer price should be market-based. In theory, this is neutral: profit is taxed where it is truly earned.

In practice, it is a nightmare. Intellectual property—software, patents, brands—has no external market. What is a “fair” price for internal use of Microsoft’s Windows? No one trades it. Multinational tax teams hire armies of economists, valuation experts, and lawyers to argue what the arm’s-length price should be. Governments also hire experts to dispute those arguments. Billions are spent on transfer pricing disputes annually.

This is where formulary apportionment enters: scrap the fiction. Just divide total profit mechanically.

How the Formula Works

A simple example: Company X earns $100 million globally. It operates in three countries with the following metrics:

Under a sales-only formula, Company X’s profit is apportioned:

• USA: ($400M / $800M) × $100M = $50M taxed in the U.S.
• Germany: ($300M / $800M) × $100M = $37.5M taxed in Germany.
• India: ($100M / $800M) × $100M = $12.5M taxed in India.

Under a three-factor formula (equal weight to sales, payroll, assets):

• USA: ((50% + 55.6% + 50%) / 3) × $100M = 51.9M taxed in the U.S.
• Germany: ((37.5% + 33.3% + 37.5%) / 3) × $100M = 36.1M in Germany.
• India: ((12.5% + 11.1% + 12.5%) / 3) × $100M = 12.0m in India.

No valuation dispute. No transfer pricing advisors. The formula runs mechanically.

Why Jurisdictions Prefer Formulary Apportionment

The U.S. uses formulary apportionment for state corporate income taxes (each state applies a three-factor sales, payroll, asset formula). It is cheaper to administer than transfer pricing and reduces disputes. Corporations know the rule upfront; states do not spend years arguing valuations.

Many developing countries have adopted formulary apportionment because they lack the technical expertise for transfer pricing disputes. The Philippines, Kenya, and others use simpler formulas rather than requiring multinational tax teams to produce transfer pricing documentation.

The EU has long debated a Common Consolidated Corporate Tax Base (CCCTB) that would use a similar approach: harmonise tax rules across member states, then allocate profits via a formula. It simplifies corporate tax, reduces avoidance incentives, and limits the “transfer price shopping” where multinationals price internal transfers to concentrate profit in low-tax havens.

The OECD’s Arm’s-Length Stance

The OECD, representing high-income countries, has resisted formulary apportionment for decades. Why? Because high-income countries benefit from the arm’s-length system. A company can locate intellectual property in Ireland (low tax) and “license” it to subsidiaries elsewhere, justifying low profits there. Multinationals naturally cluster high-margin activities (IP, finance, management) in low-tax jurisdictions. Formulary apportionment would force them to pay tax where they actually sell goods—typically high-income markets.

The arm’s-length principle protects the tax base of low-tax havens and allows multinationals to shift profits. The OECD’s Base Erosion and Profit Shifting (BEPS) project tried to tighten arm’s-length rules without abandoning them. It has had limited effect.

Recent Shift: Pillar One and Two

In 2021, the OECD reversed course, sort of. Pillar Two introduced a global minimum corporate tax (15%), which limits profit shifting. Pillar One allocates a portion of multinational profits to “market jurisdictions”—where the company sells—using a simplified formula.

Under Pillar One, a company’s profit above a threshold is split: part stays where the company is incorporated (origin state), and a fraction is allocated to countries where it has significant sales. This is quasi-formulary, though it applies only to the largest multinationals and only to excess profit above 10% return on revenue. It is a compromise: not full formulary apportionment, but a recognition that pure transfer pricing is unworkable.

Sales-Heavy vs Asset-Heavy Formulas

The choice of formula matters enormously for distribution. A sales-based formula favours countries that are big markets (USA, EU). A payroll formula favours labour-intensive manufacturing locations (Mexico, India). An asset formula favours capital-intensive sectors (oil, mining, utilities).

A company with $1B in sales in the US market but minimal production there would pay much more tax under a sales formula (most profit allocated to the US) than under an asset formula (little profit allocated, as assets are elsewhere). Conversely, a company with large factories in India but most sales in the EU would pay more under an asset formula.

This is why reaching international agreement is hard. Each country prefers a formula that allocates profit inward. The EU’s CCCTB debates have stalled partly because countries disagree on weights. France wants a higher sales weight (helps France’s consumer market). Ireland wants a lower sales weight (helps IT companies with low local sales but high IP profit).

Avoidance Under Formulary Apportionment

Formulary apportionment is not magic. Companies still have incentives to avoid it, just in different ways. Instead of manipulating transfer prices, they might:

• Artificially locate assets in low-tax jurisdictions to increase the denominator (reducing the low-tax jurisdiction’s profit share).
• Structure sales to run through low-tax subsidiaries (the low-tax subsidiary “sells” to the customer, reducing the high-tax jurisdiction’s share).
• Inflate payroll in low-tax countries through inflated management fees or consulting contracts.

A well-designed formula must be difficult to game. A sales-based formula is hardest to manipulate (customers have third-party records; hard to fake who they are). Payroll and asset bases are easier to distort through accounting tricks.

Comparison: Apportionment vs Transfer Pricing

Who Uses It

• U.S. states: Three-factor (sales, payroll, assets) formula for corporate income tax since the 1970s.
• Developing countries: Philippines, Kenya, and many others default to formulary apportionment for lack of transfer pricing expertise.
• EU: CCCTB proposals include formulary elements; not yet adopted uniformly.
• Canada: Provincially similar to U.S. states; federally uses arm’s-length pricing.
• Pillar One (OECD): Allocates fraction of excess profit using sales-based formula to market jurisdictions.

Criticism and Debate

Critics of formulary apportionment note it ignores real economic differences. A company that invests heavily in R&D earns higher-margin profit than a commodity seller. Formulary apportionment ignores this: it taxes the commodity company and the tech company identically if they have the same sales. This can be unfair and distort incentives.

Proponents counter that transfer pricing is already unfair—it is manipulated to shift profit. Formulary apportionment at least does so transparently and predictably. And for developing nations without transfer pricing expertise, it is far simpler.

The U.S. was divided historically: federal government used arm’s-length pricing; states used formulary apportionment. This created domestic disputes over allocation, but the formula was stable and widely understood. The EU faces similar pressure: some want to harmonise on formulary apportionment; others want to keep arm’s-length pricing to maintain competitiveness.

See also